Keyphrases
Type 2 Diabetic Patients
100%
Metformin
100%
Acid Activation
100%
Bile Acids
100%
GLP-1 Secretion
100%
Glucagon-like peptide-1 (GLP-1)
55%
Placebo
33%
Cholecystokinin
33%
Insulin Secretion
22%
Gallbladder Emptying
22%
Denmark
11%
Randomized Placebo-controlled Trial
11%
Pharmacotherapy
11%
Plasma Glucose
11%
Type 2 Diabetes Mellitus (T2DM)
11%
Glucose-lowering Drugs
11%
Area under the Curve
11%
Intravenous Infusion
11%
Mode of Action
11%
Glucagon Secretion
11%
Acute Setting
11%
Single-dose Treatment
11%
Glucagon
11%
Glucose Excursion
11%
Bile
11%
Metabolic Effects
11%
Diabetes Research
11%
Glucos
11%
Bile Acid Reabsorption
11%
Medicine and Dentistry
Glycon
100%
Patient with Type 2 Diabetes
100%
Secretion (Process)
100%
Single Drug Dose
100%
Glucagon Like Peptide 1
100%
Bile Acid
100%
Placebo
44%
Cholecystokinin
33%
Insulin Release
22%
Gallbladder Emptying
22%
Drug Therapy
11%
Diabetes
11%
Maturity Onset Diabetes of the Young
11%
Intravenous Drug Administration
11%
Glucagon Release
11%
Gut
11%
Glucagon
11%
Bile
11%
Biochemistry, Genetics and Molecular Biology
Single Drug Dose
100%
Secretion (Process)
100%
Glucagon-Like Peptide-1
100%
Bile Acid
100%
Cholecystokinin
37%
Insulin Release
25%
Gallbladder Emptying
25%
Glucose Blood Level
12%
Glucagon Release
12%
Glucagon
12%
Pharmacology, Toxicology and Pharmaceutical Science
Metformin
100%
Non Insulin Dependent Diabetes Mellitus
100%
Glucagon-Like Peptide-1
100%
Bile Acid
100%
Placebo
44%
Cholecystokinin
33%
Glucagon
22%
Pharmacotherapy
11%
Immunology and Microbiology
Secretion (Process)
100%
Blood Plasma
66%
Insulin Release
66%
Gallbladder Emptying
66%
Glucose Blood Level
33%
Glucagon Release
33%